Tribendimidine
- none
- N,N-bis(4-(1-dimethylamino)ethylideneaminophenyl)-1,4
-phenylene dimethylidyneamine
- 115103-15-6 N
- 3086564
- 2343161 Y
- YO6SOD6ZTJ
- ChEMBL427256 N
- DTXSID50894077
- Interactive image
- N(=C/c2ccc(\C=N\c1ccc(/N=C(/N(C)C)C)cc1)cc2)\c3ccc(\N=C(\N(C)C)C)cc3
- InChI=1S/C28H32N6/c1-21(33(3)4)31-27-15-11-25(12-16-27)29-19-23-7-9-24(10-8-23)20-30-26-13-17-28(18-14-26)32-22(2)34(5)6/h7-20H,1-6H3/b29-19+,30-20+,31-21+,32-22+ Y
- Key:XOIOGKHKNQYULW-HTNNXBMUSA-N Y
Tribendimidine is a broad-spectrum anthelmintic agent developed in China, at the National Institute of Parasitic Diseases in Shanghai. It is a derivative of amidantel.[1]
In clinical trials, it was highly effective in treating ankylostomiasis, ascariasis and enterobiasis.[2] It is also effective against clonorchiasis.[3] However, animal studies suggest it is ineffective in treating Schistosoma mansoni or Fasciola hepatica disease.[1] The drug has also performed well in trials against opisthorchiasis, curing about 70% of cases.[4]
Tribendimidine is manufactured by Shandong Xinhua Pharmaceutical Company Limited in Zibo, Shandong, China. It was approved by the China Food and Drug Administration in 2007.[citation needed]
References
- ^ a b Keiser J, Shu-Hua X, Chollet J, Tanner M, Utzinger J (March 2007). "Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini". Antimicrobial Agents and Chemotherapy. 51 (3): 1096–1098. doi:10.1128/AAC.01366-06. PMC 1803157. PMID 17194822. Free full text.
- ^ Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W (April 2005). "Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China". Acta Tropica. 94 (1): 1–14. doi:10.1016/j.actatropica.2005.01.013. PMID 15777691.
- ^ Zhang H, Liu C, Zheng Q (December 2019). "Development and application of anthelminthic drugs in China". Acta Tropica. 200: 105181. doi:10.1016/j.actatropica.2019.105181. PMID 31542370.
- ^ Kelland K (2010-11-24). "New drug shows promise against Asian liver fluke". Reuters.
- v
- t
- e
Antitrematodals (schistosomicides) |
| ||||||
---|---|---|---|---|---|---|---|
Anticestodals (taeniacides) |
|
(including
macrofilaricides)
Binds tubulin | |
---|---|
Glutamate-gated chloride channel, GABA receptor | |
NMDA |
|
Other/unknown |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e